Business

PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology

PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has executed a non-binding letter of intent with Duke University to license, through a newly-formed subsidiary, Duke's technology to identify and facilitate treatment of advanced esophageal precancer (dysplasia) during upper endoscopy. This technology—a multi-modality probe combining an

articleDuke Energy Corporation (holding Company)August 26, 20257/company/duke-energy-corporation/news/pavmed-signs-letter-of-intent-to-license-groundbreaking-endoscopic-esophageal-imaging-technology-1
PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology

About this update from Duke Energy Corporation (holding Company)

[{"type":"text","content":"Newly-formed PAVmed subsidiary to license endoscopic imaging technology designed to identify and facilitate ablative treatment of esophageal dysplasia","length":150,"tagName":"p","attribs":{}},{"type":"text","content":"Lucid Diagnostics to collaborate with PAVmed as a strategic and equity partner on the technology","length":96,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, Aug. 26, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors,  today announced that it has executed a non-binding letter of intent with Duke University to license, through a newly-formed subsidiary, Duke's technology to identify and facilitate treatment of advanced esophageal precancer (dysplasia) during upper endoscopy. This technology—a multi-modality probe combining angle-resolved low coherence interferometry (a/LCI) with optical coherence tomography (OCT)—could allow for a more efficient and effective alternative to traditional biopsies.","length":753,"tagName":"p"},{"type":"image","alt":"PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. (PRNewsfoto/PAVmed Inc.)","displaySize":"","headline":null,"caption":"PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. (PRNewsfoto/PAVmed Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":81,"url":"https://media.zenfs.com/en/prnewswire.com/b33818e0ad32f6b512ca93166f23ff80"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_9ksw7DB5omdDmUMhUY16g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE0MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b33818e0ad32f6b512ca93166f23ff80","width":400,"height":81}},"href":"https://mma.prnewswire.com/media/2011714/PAVmed_updated_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""This groundbreaking technology has the potential to fundamentally transform how we diagnose and treat esophageal precancer, while simultaneously improving patient outcomes, procedural efficiency, and healthcare resource utilization," said Nic...

More updates from Duke Energy Corporation (holding Company)

Duke Universityletter of intentendoscopic procedureLucid Diagnosticsdigital healthprecanceresophageal cancerPAVmed Inc.